June 7, 2018
Engineered proteins could improve biomanufacturing production of medicines, fuels
WEST LAFAYETTE, Ind. – Purdue University researchers have developed a series of engineered proteins that could improve biomanufacturing processes for the production of biofuels, pharmaceuticals and commodity chemicals.
The buildup of toxic materials during the production process can damage cell health and typically lowers the overall amount of product that is made. Few tools are available to broadly address this issue.
Kevin Solomon, an assistant professor in the Purdue Department of Agricultural and Biological Engineering, and his team developed a series of engineered proteins derived from elastin-like polypeptides, or single linear chains of amino acids. ELPs have an inverse phase change property of aggregating in response to specific environmental triggers such as temperature and pH. The researchers fused these ELPs to transcription factors, proteins that bind to DNA, to control gene expression and regulate the buildup of toxic materials.
“Our transcriptional regulators recognize generic signals of toxicity and, thus, can be applied to pathways for the production of many compounds,” Solomon said. “These regulators are tunable, by controlling the ELP structure, to create feedback that only triggers at preprogrammed setpoints.”
The regulators are easily tailored to different biomanufacturing processes by selecting an appropriate transition setpoint for a given production pathway. They provide a generic tunable platform with clear design rules that can be developed for any process. Current approaches are product-specific and difficult to adapt.
“Our system is programmable, meaning that we can make specific changes in the ELP sequence that allow us to tailor its transition property, therefore, allowing us to create a library of ELPs that transition under various conditions,” said Logan Readnour, a graduate student in agricultural and biological engineering and a member of Solomon’s research team. “We are able to target specific genes for regulation and because we use a transcription factor that is not native to the cell, it does not interfere with the native processes already present within the cell.”
By improving cell health during the biomanufacturing process, the researchers hope to optimize yields of valuable products such as medicines and fuels.
“This technology will help us move to more sustainable bioproduction that replaces or complements products from dwindling petroleum reserves, while using less harsh and dangerous chemicals,” Solomon said.
A patent application has been filed by the Purdue Office of Technology Commercialization and the technology is available for licensing.
About Purdue Office of Technology Commercialization
The Purdue Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university's academic activities. The office is managed by the Purdue Research Foundation, which received the 2016 Innovation and Economic Prosperity Universities Award for Innovation from the Association of Public and Land-grant Universities. For more information about funding and investment opportunities in startups based on a Purdue innovation, contact the Purdue Foundry at email@example.com. For more information on licensing a Purdue innovation, contact the Office of Technology Commercialization at firstname.lastname@example.org. The Purdue Research Foundation is a private, nonprofit foundation created to advance the mission of Purdue University.
Purdue Research Foundation contact: Chris Adam, 765-588-3341, email@example.com
Sources: Kevin Solomon, firstname.lastname@example.org
Logan Readnour, email@example.com